Ibandronsyre hæmmer selektivt osteoklastaktiviteten, reducerer knogleresorptionen og mindsker herved skeletkomplikationerne ved den maligne sygdom.
Ibandronic acid selectively inhibits osteoclast activity, reducing bone resorption and thereby reducing skeletal complications of the malignant disease.